CDXS logo

Codexis (CDXS) News & Sentiment

Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
CDXS
globenewswire.comMarch 7, 2025

REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.

Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
CDXS
globenewswire.comFebruary 14, 2025

REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.

Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
CDXS
globenewswire.comJanuary 10, 2025

REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 23,000 shares of Codexis common stock and (ii) 11,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.

Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
CDXS
globenewswire.comDecember 6, 2024

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 168,400 shares of Codexis common stock and (ii) 39,750 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan.

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
CDXS
globenewswire.comNovember 19, 2024

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
CDXS
globenewswire.comNovember 11, 2024

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.

Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
Codexis Announces New Employment Inducement Grants
CDXS
globenewswire.comNovember 8, 2024

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company's 2024 Inducement Plan.

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript
Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript
Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript
CDXS
seekingalpha.comOctober 31, 2024

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
CDXS
zacks.comOctober 31, 2024

Codexis (CDXS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.26 per share a year ago.

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
CDXS
globenewswire.comOctober 24, 2024

Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3